NCT03866382 2026-04-16
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
722 trialsNCT05616650 2026-04-16
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06171139 2026-04-16
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
University of California, San Francisco
Phase NA Recruiting
NCT06347705 2026-04-16
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06439225 2026-04-16
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06780670 2026-04-16
PSMAcTION
Novartis
Phase 2/3 Recruiting
NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT04693377 2026-04-15
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06161506 2026-04-15
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06511141 2026-04-15
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics, Inc.
Phase NA Recruiting
NCT06615752 2026-04-15
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Phase 1/2 Recruiting
NCT07002320 2026-04-15
ASpiRE
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT07111507 2026-04-15
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT05487846 2026-04-14
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Thomas Jefferson University
Phase NA Recruiting
NCT05847166 2026-04-14
A Phase 2/3,PSMA-T4, Prostate Cancer
NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom
Phase NA Recruiting
NCT06122584 2026-04-14
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH
Phase 3 Recruiting
NCT06235697 2026-04-14
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT04071236 2026-04-13
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT05313191 2026-04-13
ReRT
The New York Proton Center
Phase NA Recruiting
NCT05413850 2026-04-13
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT05558241 2026-04-13
MUSIC-AS
University of Alberta
Phase NA Recruiting
NCT05691465 2026-04-13
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06190899 2026-04-13
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
Phase 1/2 Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06594926 2026-04-13
WOMBAT
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Recruiting
NCT06610825 2026-04-13
CaRPET
Washington D.C. Veterans Affairs Medical Center
Phase 2 Recruiting
NCT06616155 2026-04-13
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT06925737 2026-04-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06995898 2026-04-13
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT07082920 2026-04-13
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07093177 2026-04-13
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
University of Utah
Phase NA Recruiting
NCT07220720 2026-04-13
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
University of Florida
Phase 2 Recruiting
NCT07319871 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT00588185 2026-04-09
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT05710861 2026-04-09
EMERHIT
University Hospital, Bordeaux
Phase NA Recruiting
NCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06056830 2026-04-09
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06801236 2026-04-09
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics Limited
Phase 1 Recruiting
NCT06970847 2026-04-09
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT07520916 2026-04-09
MPE-RP
Giresun University
Phase NA Recruiting
NCT02706561 2026-04-08
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT04633252 2026-04-08
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting